<DOC>
	<DOCNO>NCT01824238</DOCNO>
	<brief_summary>This study evaluate effect anacetrapib ( MK-0859 ) low-density lipoprotein-cholesterol ( LDL-C ) compare placebo Japanese participant heterozygous familial hypercholesterolemia add exist statin lipid-modifying therapy .</brief_summary>
	<brief_title>A Study Safety Efficacy Anacetrapib ( MK-0859 ) When Added Ongoing Statin Therapy Japanese Participants With Heterozygous Familial Hypercholesterolemia ( MK-0859-050 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>If female , reproductive potential Diagnosed heterozygous familial hypercholesterolemia Have treat appropriate stable dose statinÂ± lipidlowering medication ( ) least 6 week Previously participate study cholesteryl ester transfer protein ( CETP ) inhibitor Homozygous familial hypercholesterolemia Severe chronic heart failure Uncontrolled cardiac arrhythmia , myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) , unstable angina , stroke within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>